Table 2

Pathological features of pancreatic cancer in p16-Leiden mutation carriers

Expression of p53: I, no expression (<1% positive); II, low expression (1% less than positive-stained nuclei <25%); III, moderate expression (25% less than positive-stained nuclei <75%); and IV, high expression (>75% positive). The immunoreactivity score for COX-2 was divided into four categories: absent; weak (1+); moderate (2+); and strong (3+). A score of ≥2+ was considered as positive (overexpression).

No.Tissue availableHistologyT percentageLOHK-ras-2IHC
p16Tp53Smad4COX-2
1WhippleCDA50NoGAT1+
2Duodenum bpCDACGT4Pos
3WhippleCDA40NoGAT1+Pos
4Pancreas bpCDAa4+Pos
5Duodenum bpCDAa4+Pos
6Liver bpCDA50YesGAT4+Pos
7AutopsyCDA40NoGTT1Pos
8AutopsyCDA>50Yesb1Pos
9AutopsyNCc>40NoGTT2Pos
10AutopsyCDA40NoGAT1Pos
11Pancreas bpCDAGTT3+Pos
12Liver bpCDAGATb4+Pos
  • a Only few tumor cells.

  • b No internal positive control.

  • c NC: neuroendocrine carcinoma; Pos, positive.